IDC112

IDC112 is an early-stage, first-in-class monoclonal antibody being developed by Prestige Biopharma for the treatment of solid tumors. Currently in the lead identification phase, the drug is part of Prestige Biopharma's innovative drug pipeline, which focuses on novel targets and first-in-class biologics. While the specific molecular target and mechanism of action have not been publicly disclosed, the candidate is designed to address unmet needs in oncology by targeting pathways distinct from current standard-of-care therapies. As a first-in-class antibody, it represents a novel approach to treating malignant growths, though it remains in the discovery stage of the development lifecycle.